AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19215685 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 45
Study 17123214 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary in‐patient treatment programme
Number of subjects: 483
Study 17123214 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary functional restoration treatment for patients with high risk of chronification
Number of subjects: 483
Study 17123214 — intervention group
Group type: COMPARATOR
Intervention: Control group with standard rehabilitation programme
Number of subjects: 483
Study 15518605 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative coronary revascularization recommendations by cardiologists
Number of subjects: 12
Study 15518605 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred method of revascularization
Number of subjects: 12
Study 11573589 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid enriched solution (AMIPAREN) infusion at a rate of 166 kJ h(‐1) in AA-PTC group
Number of subjects: 60
Study 11573589 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid enriched solution (AMIPAREN) infusion at a rate of 166 kJ h(‐1) in AA-TOF group
Number of subjects: 60
Study 11573589 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid enriched solution (AMIPAREN) infusion in AA-PTC group
Number of subjects: 60
Study 11573589 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid enriched solution (AMIPAREN) infusion in AA-TOF group
Number of subjects: 60
Study 11573589 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in C-PTC group
Number of subjects: 60
Study 11573589 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in C-TOF group
Number of subjects: 60
Study 11573589 — intervention group
Group type: COMPARATOR
Intervention: Normal saline in C-PTC and C-TOF groups
Number of subjects: 60
Study 9028489 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophan membrane
Number of subjects: 8
Study 9028489 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane
Number of subjects: 8
Study 9028489 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods of Kt/V‐urea calculation
Number of subjects: 8
Study 8332615 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cocaine (2 mg/kg)
Number of subjects: 30
Study 8332615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8332615 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose cocaine (1 mg/kg)
Number of subjects: 30
Study 3511017 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins supplemented with iron
Number of subjects: 0
Study 3511017 — intervention group
Group type: COMPARATOR
Intervention: Vitamins alone
Number of subjects: 0
Study 30355189 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VNS
Number of subjects: 17
Study 30355189 — intervention group
Group type: COMPARATOR
Intervention: Control VNS
Number of subjects: 17
Study 27196998 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital ticagrelor 180 mg loading dose
Number of subjects: 37
Study 27196998 — intervention group
Group type: COMPARATOR
Intervention: In-hospital ticagrelor 180 mg loading dose
Number of subjects: 37
Study 27196998 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine administration
Number of subjects: 37
Study 25300611 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendoscopy group
Number of subjects: 2448
Study 25300611 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration group
Number of subjects: 2448
Study 25300611 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy group
Number of subjects: 2448
Study 25300611 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 2448
Study 22965994 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous c-kit(+) cardiac stem cells (CSCs)
Number of subjects: 33
Study 21215151 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-aortic vacant guide wire
Number of subjects: 86
Study 21215151 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (group A)
Number of subjects: 86
Study 18251358 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal estradiol cream
Number of subjects: 10
Study 18251358 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 10
Study 16545642 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT (multislice computed tomography)
Number of subjects: 67
Study 16545642 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpography
Number of subjects: 67
Study 16545642 — intervention group
Group type: COMPARATOR
Intervention: Conventional invasive coronary imaging (quantitative coronary angiography and IVUS)
Number of subjects: 67
Study 12845387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (GB) therapy, 80 mg three times daily
Number of subjects: 8
Study 10980877 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 10980877 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 8623871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonclosure of the visceral peritoneum
Number of subjects: 549
Study 8623871 — intervention group
Group type: COMPARATOR
Intervention: Closure of the visceral peritoneum
Number of subjects: 549
Study 1458890 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 180
Study 1458890 — intervention group
Group type: COMPARATOR
Intervention: 1 mg gemeprost as a vaginal pessary
Number of subjects: 180
Study 1458890 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment in the sitting-room
Number of subjects: 180
Study 1458890 — intervention group
Group type: COMPARATOR
Intervention: Treatment in the ward
Number of subjects: 180
Study 1458890 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction with method of treatment
Number of subjects: 180
Study 1458890 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation of method to friends
Number of subjects: 180
Study 1458890 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for partner or friend presence
Number of subjects: 180
Study 1458890 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference to stay in hospital after administration of prostaglandin
Number of subjects: 180
Study 3917698 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter removal and later replacement
Number of subjects: 113
Study 3917698 — intervention group
Group type: COMPARATOR
Intervention: Replacement over a guidewire
Number of subjects: 113
Study 3917698 — intervention group
Group type: COMPARATOR
Intervention: Guidewire procedure
Number of subjects: 113
Study 31173939 — intervention group
Group type: EXPERIMENTAL
Intervention: HT with bilateral annexectomy or ovarian conservation using 3-mm instruments (group A)
Number of subjects: 32
Study 31173939 — intervention group
Group type: COMPARATOR
Intervention: Conventional 5-mm instruments (group B)
Number of subjects: 32
Study 29633139 — intervention group
Group type: EXPERIMENTAL
Intervention: Study-enhanced PRO completion rates (web-based PHR, IVR calls, live outreach)
Number of subjects: 831
Study 29633139 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO completion at 3 months
Number of subjects: 831
Study 29633139 — intervention group
Group type: EXPERIMENTAL
Intervention: Response by method of PRO administration
Number of subjects: 831
Study 27511452 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) administration
Number of subjects: 117
Study 27511452 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 117
Study 25686811 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care (TBCC)
Number of subjects: 364
Study 25686811 — intervention group
Group type: COMPARATOR
Intervention: Practice-based collaborative care (PBCC)
Number of subjects: 364
Study 23489530 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance (HOMA >1.24)
Number of subjects: 250
Study 23489530 — intervention group
Group type: COMPARATOR
Intervention: Insulin resistance (HOMA <1.24)
Number of subjects: 250
Study 23489530 — intervention group
Group type: COMPARATOR
Intervention: Baseline LVH (present)
Number of subjects: 250
Study 23489530 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline LVH (not present)
Number of subjects: 250
Study 19947900 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 166
Study 19947900 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium as needed (Control)
Number of subjects: 166
Study 18155331 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (ON)
Number of subjects: 24
Study 18155331 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's disease (OFF)
Number of subjects: 24
Study 18155331 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 16166441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-methoxyestradiol 1,200 mg/d
Number of subjects: 33
Study 16166441 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-methoxyestradiol 400 mg/d
Number of subjects: 33
Study 15709726 — intervention group
Group type: EXPERIMENTAL
Intervention: STA-MCA anastomosis combined with best medical therapy
Number of subjects: 930
Study 15709726 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 930
Study 15709726 — intervention group
Group type: EXPERIMENTAL
Intervention: STA-MCA anastomosis
Number of subjects: 930
Study 10588962 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antiandrogen therapy (goserelin or bilateral orchiectomy)
Number of subjects: 98
Study 8759655 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.i.d.
Number of subjects: 88
Study 8759655 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg/day
Number of subjects: 88
Study 1868960 — intervention group
Group type: EXPERIMENTAL
Intervention: Premixture 3/7 (Actraphane HM)
Number of subjects: 20
Study 1868960 — intervention group
Group type: COMPARATOR
Intervention: Extemporary mixtures of regular + NPH at mixing ratios from 2/8 to 4/6
Number of subjects: 20
Study 6275706 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (Premarin) and medrogestone (Colpro)
Number of subjects: 23
Study 6275706 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (Dixarit)
Number of subjects: 23
Study 6275706 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 asymptomatic postmenopausal women)
Number of subjects: 23
Study 30576544 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant 30 mg
Number of subjects: 402
Study 30576544 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant 100 mg
Number of subjects: 402
Study 30576544 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant 300 mg
Number of subjects: 402
Study 29759434 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat electrophysiology study after 2 months
Number of subjects: 80
Study 29759434 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 80
Study 26511056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow derived mononuclear cell (BMMNC) administration
Number of subjects: 109
Study 26511056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 25052076 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated tube voltage selection (ATVS)
Number of subjects: 72
Study 21905001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 200 mg
Number of subjects: 986
Study 21905001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab 500 mg
Number of subjects: 986
Study 21905001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 986
Study 19678774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba L. tablets (40 mg leaf extracts), taken three times a day from the 16th day of the menstrual cycle to the 5th day of the next cycle.
Number of subjects: 90
Study 19678774 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken three times a day from the 16th day of the menstrual cycle to the 5th day of the next cycle.
Number of subjects: 90
Study 17183512 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary structured home training programme, ergonomic advice, wrist and/or night bandages as necessary.
Number of subjects: 78
Study 17183512 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary structured home training programme.
Number of subjects: 78
Study 17183512 — intervention group
Group type: COMPARATOR
Intervention: Control group received conventional treatment (corticosteroid injections, stretching, or no intervention).
Number of subjects: 78
Study 15334379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreas Tonic (2 capsules 3 times a day) for 3 months
Number of subjects: 36
Study 15334379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15334379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreas Tonic
Number of subjects: 36
Study 15334379 — intervention group
Group type: COMPARATOR
Intervention: Pancreas Tonic and Placebo
Number of subjects: 36
Study 12015475 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0
Study 12015475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12015475 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0
Study 11801985 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermis placement during superficial lobe parotidectomy
Number of subjects: 64
Study 11801985 — intervention group
Group type: COMPARATOR
Intervention: Superficial lobe parotidectomy without acellular dermis
Number of subjects: 64
Study 9274439 — intervention group
Group type: EXPERIMENTAL
Intervention: exemestane 0.5 mg
Number of subjects: 20
Study 9274439 — intervention group
Group type: EXPERIMENTAL
Intervention: exemestane 1 mg
Number of subjects: 20
Study 9274439 — intervention group
Group type: EXPERIMENTAL
Intervention: exemestane 2.5 mg
Number of subjects: 20
Study 9274439 — intervention group
Group type: EXPERIMENTAL
Intervention: exemestane 5 mg
Number of subjects: 20
Study 9274439 — intervention group
Group type: EXPERIMENTAL
Intervention: exemestane (all doses)
Number of subjects: 20
Study 7686279 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion (mode A)
Number of subjects: 8
Study 7686279 — intervention group
Group type: COMPARATOR
Intervention: Continuous basal rate subcutaneous infusion + PCA (mode B)
Number of subjects: 8
Study 3530126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-Vancomycin (CV)
Number of subjects: 79
Study 3530126 — intervention group
Group type: COMPARATOR
Intervention: KGC (Ceftazidime, Cephalothin, Gentamicin, Carbenicillin)
Number of subjects: 79
Study 3530126 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime alone
Number of subjects: 79
Study 29785872 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside fiber bronchoscope for sputum suction and alveolar lavage
Number of subjects: 106
Study 29785872 — intervention group
Group type: COMPARATOR
Intervention: Conventional suction catheter
Number of subjects: 106
Study 27510536 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking 300 mL H2O during the 4-hour period
Number of subjects: 101
Study 27510536 — intervention group
Group type: COMPARATOR
Intervention: No water consumption (Control)
Number of subjects: 101
Study 27510536 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking water
Number of subjects: 101
Study 23581276 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial sonography (TCS) of basal ganglia
Number of subjects: 14
Study 23581276 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 14
Study 23175912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Movement Therapy (DMT), 2 times a week for 4 weeks
Number of subjects: 50
Study 23175912 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational sessions), 2 times a week for 4 weeks
Number of subjects: 50
Study 20631559 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic agents (especially clozapine) in patients with comorbid psychosis (DD)
Number of subjects: 43
Study 20631559 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic agents in patients without comorbid psychosis (SD)
Number of subjects: 43
Study 18202708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2% monotherapy
Number of subjects: 28
Study 18202708 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.50% monotherapy
Number of subjects: 28
Study 18202708 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination
Number of subjects: 28
Study 15669934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care based on active involvement of patients in their nutritional care
Number of subjects: 253
Study 15669934 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 253
Study 12923369 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 60
Study 12923369 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 60
Study 12923369 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 60
Study 10344454 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg day(‐1) vitamin E supplementation for 28 days
Number of subjects: 0
Study 10344454 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin E supplementation)
Number of subjects: 0
Study 10344454 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (exhaustive exercise including concentric‐eccentric contractions)
Number of subjects: 0
Study 10344454 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 10344454 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 0
Study 8949977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and exercise intervention for one year
Number of subjects: 0
Study 8949977 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 8949977 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and exercise intervention
Number of subjects: 0
Study 8949977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Number of subjects: 0
Study 1845591 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31024092 — intervention group
Group type: EXPERIMENTAL
Intervention: High dairy condition (four daily servings of whole milk or full-fat dairy products)
Number of subjects: 60
Study 30830076 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% hyaluronic acid
Number of subjects: 43
Study 30830076 — intervention group
Group type: EXPERIMENTAL
Intervention: Tear substitute with antioxidant properties (Artelac Rebalance drops)
Number of subjects: 43
Study 30830076 — intervention group
Group type: COMPARATOR
Intervention: 0.05% Cyclosporin A (CyA) 2 times a day
Number of subjects: 43
Study 28118425 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate injections
Number of subjects: 20
Study 28118425 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine injections
Number of subjects: 20
Study 28118425 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline injections
Number of subjects: 20
Study 28118425 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 kg pressure
Number of subjects: 20
Study 28118425 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate injections with 0.5 kg and 1.0 kg pressure
Number of subjects: 20
Study 28118425 — intervention group
Group type: EXPERIMENTAL
Intervention: COG coordinates
Number of subjects: 20
Study 25501607 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplements with added vitamins and minerals (LNS-VM)
Number of subjects: 813
Study 25501607 — intervention group
Group type: COMPARATOR
Intervention: Lipid-based nutritional supplements without added vitamins and minerals (LNS)
Number of subjects: 813
Study 24602760 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (rituximab 375 mg/m² weekly for 4 weeks followed by 12 infusions at 2-month intervals for 2 years)
Number of subjects: 379
Study 24602760 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab induction (rituximab 375 mg/m² weekly for 4 weeks)
Number of subjects: 379
Study 24602760 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 379
Study 24602760 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab
Number of subjects: 379
Study 24602760 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab induction
Number of subjects: 379
Study 24602760 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab groups (both induction and maintenance)
Number of subjects: 379
Study 23079877 — intervention group
Group type: EXPERIMENTAL
Intervention: Long leg cast with knee flexed 10° and encouraged to bear weight as tolerated
Number of subjects: 81
Study 23079877 — intervention group
Group type: COMPARATOR
Intervention: Long leg cast with knee flexed 60° and instructed not to bear weight
Number of subjects: 81
Study 19774308 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A mixed with 2 ml saline
Number of subjects: 0
Study 19774308 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A mixed with 8 ml saline
Number of subjects: 0
Study 17324975 — intervention group
Group type: EXPERIMENTAL
Intervention: Installation of a standard retrofit insulation package
Number of subjects: 4407
Study 14684396 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma lycopene (increasing quartiles)
Number of subjects: 483
Study 14684396 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma carotenoids (individual addition)
Number of subjects: 483
Study 11277343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hairgain (active preparation)
Number of subjects: 60
Study 9533060 — intervention group
Group type: COMPARATOR
Intervention: Eprosartan 400 mg alone
Number of subjects: 17
Study 9533060 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan 400 mg with ranitidine 150 mg after 3 days of ranitidine 150 mg twice daily
Number of subjects: 17
Study 8029793 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - ardeparin
Number of subjects: 0
Study 8029793 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 0